Cerevast Licenses Ultrasound Neuromodulation Technologies from Arizona State University for Post-Stroke Rehabilitation

ASU Technology TransferREDMOND, WA and TEMPE, AZ – August 3, 2016 – Cerevast Medical, Inc., a medical technology company that develops medical products for the treatment of neurologic disorders, has licensed several technologies from Arizona State University to be used in innovative post-stroke rehabilitation devices. The technologies were developed by Dr. Jamie Tyler in the School of Biological and Health Systems Engineering, one of the Ira A. Fulton Schools of Engineering at ASU.

“Dr. Tyler is a recognized leader in the field of modulating cellular activity using ultrasound,” said Bradford Zakes, Cerevast president and CEO. “These technologies augment our existing IP portfolio and will enable the development of sophisticated, non-invasive new therapies for post-stroke brain rehabilitation.”

The CDC reports nearly 800,000 stroke victims in the United States each year. The vast majority of stroke victims survive, but with injuries to the brain that can severely impact their ability to work or care for themselves.

Transcranial Ultrasound (TUS) Therapy transmits ultrasonic energy into the motor cortex region of the brain to promote recovery and rehabilitation following a stroke. When used in combination with traditional physical therapy, TUS increases neuroplasticity, making it easier for the brain to route new pathways to regain physical movements.

Unlike competing therapies that required the surgical implantation of electrodes, TUS can be performed non-invasively. It also reaches deeper regions of the brain than other non-invasive technologies like transcranial magnetic stimulation. In addition, TUS is the only non-invasive brain stimulation technology to receive regulatory approval outside the U.S. for post-stroke recovery.

“The field of neuromodulation—which has now drawn extensive interest from federal funding agencies and other labs—really began moving again through the work done at ASU,” said Dr. Tyler. “This is an area of medicine that has tremendous potential for treating a wide range of neurologic disorders and I am very pleased to see a company with the accomplishments of Cerevast using these technologies.”

The license was completed through Arizona Technology Enterprises (AzTE), the exclusive intellectual property management and technology transfer organization of Arizona State University.